The Clinical Efficacy and Safety of Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE ，a Multicentre Observational Study
The aim of this study was to observe the clinical efficacy and safety of rituximab (RTX) combination with telitacicept (TA) in patients of systemic lupus erythematosus secondary antiphospholipid syndrome (APS).
• 1.Patients who meet 2006 Sapporo classification criteria of APS or 2020 nonstandard APS performance；
⁃ Patients who meet 1997 or 2019 SLE classification criteria ;
⁃ Positive LA /ACL/ aβ2GPI ,on two or more occasions, at least 12 weeks apart;
⁃ with at least one extra-criteria manifestations of APS, including thrombocytopenia, hemolytic anemia, nephropathy, valve heart disease ,skin ulcer and arterial or deep vein thrombosis;
⁃ Maintain a stable base treatment regimen for at least 4 weeks before screening; Basic treatment includes anticoagulants/antiplatelet agents, glucocorticoids, and hydroxychloroquine;
⁃ No response, intolerance or dependence on glucocorticoids and immunosuppressants;
⁃ Patients who had previously used beliumab or Telitacicept could be enrolled in the study after 12 weeks of discontinuation;
⁃ Age ≥18 years;
⁃ Signed Informed consent.